about us

Wecomput Technology Co., Ltd., as one of the leading computational CRO in China for Global, is committed to empowering drug discovery innovation by providing comprehensive computional solutions for biomedicine, integrating cutting-edge technologies like artificial intelligence, biophysics, high-performance computing, etc. Wecomput has created WeMol, a unique software platform for drug molecule generation, design and simulation, covering proteins, antibodies, RNAs, and small molecules.

In 2021, Wecomput received equity investment from Sequoia Capital China and was selected into the NVIDIA Inception program. So far, Wecomput have established collaborations with 300+ customers and partners all over the world, covering many biopharmas, colleges, hospitals, and institutes, e.g., Otsuka, NVIDIA, University of California, Karolinska Institutet, CDC, Simcere, Shanghai Pharma, SinoPharm, WuXi AppTec, etc.